Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
31
RNA Quote, Financials, Valuation and Earnings
Last price:
$29.16
Seasonality move
:
3.75%
Day range:
$28.36 - $29.68
52-week range:
$21.51 - $56.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
400.69x
P/B ratio:
2.66x
Volume:
1.5M
Avg. volume:
1.4M
1-year change:
-22.07%
Market cap:
$3.5B
Revenue:
$10.9M
EPS (TTM):
-$3.00
Analysts' Opinion
-
Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $68.31, Avidity Biosciences has an estimated upside of 133.07% from its current price of $29.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $54.00 representing 100% downside risk from its current price of $29.31.
Fair Value
-
According to the consensus of 10 analysts, Avidity Biosciences has 133.07% upside to fair value with a price target of $68.31 per share.
RNA vs. S&P 500
-
Over the past 5 trading days, Avidity Biosciences has underperformed the S&P 500 by -8.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avidity Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avidity Biosciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Avidity Biosciences reported revenues of $1.6M.
Earnings Growth
-
Avidity Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Avidity Biosciences reported earnings per share of -$0.90.
Enterprise value:
2.2B
EV / Invested capital:
1.62x
Price / LTM sales:
400.69x
EV / EBIT:
--
EV / Revenue:
241.13x
PEG ratio (5yr expected):
-7.23x
EV / Free cash flow:
-5.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-26.51%
Net Income Margin (TTM):
-4136%
Return On Equity:
-29.26%
Return On Invested Capital:
-29.26%
Operating Margin:
-8360.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $9.7M | $10.9M | $8.9M | $3.5M | $1.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$202M | -$255.2M | -$433.3M | -$77.2M | -$131.5M | |
| EBITDA | -$200.6M | -$252.8M | -$430.3M | -$76.5M | -$130.7M | |
| Diluted EPS | -$3.36 | -$2.96 | -$3.00 | -$0.79 | -$0.90 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $312M | $404.8M | $597.1M | $934.5M | $1.4B | |
| Total Assets | $314.8M | $421.1M | $614M | $951.5M | $1.5B | |
| Current Liabilities | $17.5M | $30.9M | $48.1M | $75M | $84.9M | |
| Total Liabilities | $28.6M | $45.4M | $55.1M | $120.6M | $130.4M | |
| Total Equity | $286.1M | $375.7M | $558.9M | $830.9M | $1.3B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$155.7M | -$140.5M | -$355.3M | -$70.4M | -$124.8M | |
| Cash From Investing | -$210.2M | $32.9M | -$664.3M | -$32.7M | $157.2M | |
| Cash From Financing | $345M | $460.3M | $804.8M | $389.4M | $1.9M | |
| Free Cash Flow | -$159.5M | -$143.8M | -$365.2M | -$71.3M | -$128.6M | |
RNA
Sector
Market Cap
$3.5B
$32.8M
Price % of 52-Week High
52.34%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
-21.26%
-0.74%
1-Year Price Total Return
-22.07%
-35.38%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$30.87
200-day SMA
Sell
Level
$35.44
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$31.93
Relative Strength Index (RSI14)
Sell
Level
41.48
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-90.3326
50-day SMA
Sell
Level
$30.22
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.5726)
Buy
CA Score
(Annual)
Level (-0.2832)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.4137)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Stock Forecast FAQ
In the current month, RNA has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RNA average analyst price target in the past 3 months is $68.31.
-
Where Will Avidity Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avidity Biosciences share price will rise to $68.31 per share over the next 12 months.
-
What Do Analysts Say About Avidity Biosciences?
Analysts are divided on their view about Avidity Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avidity Biosciences is a Sell and believe this share price will drop from its current level to $54.00.
-
What Is Avidity Biosciences's Price Target?
The price target for Avidity Biosciences over the next 1-year time period is forecast to be $68.31 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avidity Biosciences is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RNA?
You can purchase shares of Avidity Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avidity Biosciences shares.
-
What Is The Avidity Biosciences Share Price Today?
Avidity Biosciences was last trading at $29.16 per share. This represents the most recent stock quote for Avidity Biosciences. Yesterday, Avidity Biosciences closed at $29.31 per share.
-
How To Buy Avidity Biosciences Stock Online?
In order to purchase Avidity Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
86
GMS alert for Jun 24
GMS [GMS] is up 0.03% over the past day.
Buy
54
SMLR alert for Jun 23
Semler Scientific [SMLR] is up 16.13% over the past day.
Sell
37
GXO alert for Jun 24
GXO Logistics [GXO] is up 2.42% over the past day.
